

IntelGenx Technologies Corp.  
Form 8-K  
February 04, 2014

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**Current Report**  
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**February 4, 2014**  
Date of Report (Date of Earliest Event Reported)

**IntelGenx Technologies Corp.**  
(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**000-31187**  
(Commission File  
Number)

**870638336**  
(IRS Employer Identification  
No.)

**6425 Abrams, Ville St- Laurent, Quebec, Canada**  
(Address of principal executive offices)

**H4S 1X9**  
(Zip Code)

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

---

**Item 8.01 Other Events - News Release**

**IntelGenx and RedHill Biopharma Receive Complete Response Letter from FDA for VersaFilm Oral Film Product for Acute Migraines**

Exhibit Description

99.1 Press Release

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGENX TECHNOLOGIES CORP.**

Dated: February 4, 2014

By: */s/ Rajiv Khosla*

-----  
Rajiv Khosla  
President and Chief  
Executive Officer